Introduction {#S1}
============

According to the International Diabetes Federation (IDF), 8.3% of adults worldwide -- 370 ­million people -- have type-2 diabetes (T2D), and the number of people with the disease is set to rise beyond 592 million in under 25 years ([@B1]). Although there are many drugs available for diabetes, none of them safely and durably prevent or reverse disease progress and its associated comorbidities. Poor diet, sedentary lifestyle, and obesity are considered major risk factors for diabetes. Inappropriate fuel handling by adipose tissue, liver, and skeletal muscle, combined with ectopic lipid deposition in key metabolic organs (such as liver, pancreas, muscle, and heart) have been hypothesized to play a significant role in the development of insulin resistance. Insulin resistance increases the overall burden on β-cells, which over time leads to β-cell failure and development of T2D.

Adipose tissue can be grossly divided into two major depots, white adipose tissue (WAT) and brown adipose tissue (BAT). WAT stores excess energy as triglycerides (TGs), which can be mobilized by lipolysis to generate free fatty acids (FFAs) for use by other tissues. BAT, on the other hand, is the main site of non-shivering thermogenesis (NST), which requires a brown adipocyte-specific protein called uncoupling protein 1 (UCP1).

Non-shivering thermogenesis by BAT is an interesting target for the treatment of metabolic disease due to the high metabolic capacity of BAT. BAT is highly vascularized and richly innervated by sympathetic nerves, and its activation is predominantly regulated by the sympathetic nerve system via β-adrenergic receptors (β-ARs). Enhancing energy expenditure (EE) through activation of NST by β~3~-adrenergic receptor (β~3~-AR) agonists has been investigated as an alternative to inhibition of food intake for bodyweight loss. This has, however, been unsuccessful in human clinical trials. This lack of effect on EE was partly attributed to negligible BAT function in adult humans compared to the situation in rodents.

The rediscovery of BAT in the adult human in 2007, and the subsequent demonstration of functional involvement of human BAT in NST have revitalized this area ([@B2]--[@B5]). In addition, the presence of brown-like adipocytes in WAT \[referred to as beige or brown-in-white (brite) adipocytes\] further increased the interest in brown adipocyte biology, as WAT mass is relatively large and any increase in cellular energetics in this tissue may have a significant impact on whole-body metabolism and EE. The beige nomenclature will be used for this review. Utilization of FFAs during NST could lead to depletion of brown and or beige adipocytes' lipid stores, which may result in redistribution of fuels \[including glucose and non-esterified fatty acids (NEFA)\] toward brown and beige adipocytes. In turn, this could lead to a reduced fuel over-supply to other metabolic organs (heart, skeletal muscle, and liver) and, thus, improved insulin sensitivity (Figure [1](#F1){ref-type="fig"}).

![**White adipose tissue stores excess energy as triglycerides that can be mobilized by lipolysis to generate FFA for use by other tissues**. BAT is the main site of NST, which is carried out by UCP1. Beige adipocytes have uncoupling capabilities similar to brown adipocytes, but are found in what is normally considered WAT. Appropriate partitioning and oxidation of fatty acids into BAT, WAT, beige adipocytes, and other metabolic organs can reduce ectopic fat deposition in metabolic organs, resulting in improved insulin sensitivity. Green arrows indicate appropriate partitioning and red arrows indicate inappropriate partitioning.](fendo-06-00174-g001){#F1}

Transcriptional and hormonal regulation of the "browning" program of adipose stem cells and characterization of the molecular signature have been reviewed extensively elsewhere ([@B6]--[@B12]). This paper focuses on the metabolic potential of BAT and beige adipocytes, how these systems can be manipulated by pharmacological means, and how to assess if a brown adipocyte phenotype has been achieved by pharmacological intervention. Finally, we discuss the challenges of drug discovery in this area by reviewing three classes of clinically investigated pharmacological agents that regulate various aspects of BAT and beige adipocyte function: thiazolidinedione (TZD) PPARγ agonists, β~3~-AR agonists, and fibroblast growth factor 21 (FGF21) analogs.

Brown Adipose Tissue in Adult Humans {#S2}
====================================

Typically, BAT is located in the interscapular (iBAT), cervical, auxiliary, perirenal and paraaortic areas of animals or human infants ([@B13]--[@B15]). In adult humans, BAT depots have a diffuse anatomic distribution, with mixtures of white and beige adipocytes, seeming to coexist in close proximity. Beige adipocytes have also been reported to arise in what are normally considered WAT depots (such as inguinal adipose in rodents) in response to various stimuli such as cold, TZDs, and β-AR agonists ([@B9]). In humans, beige adipocytes were found in the WAT of pheochromocytoma patients due to the presence of catecholamine-secreting tumors ([@B16], [@B17]) and in the subcutaneous adipose of severely burned patients where heat loss is increased and who experience prolonged adrenergic stress ([@B18]). Both lineage-tracing studies and transcriptional profiling of classical brown and beige adipocytes indicate that these two cell types seem to originate developmentally from distinct cell lineages. Classical brown adipocytes in interscapular BAT arise from precursors that are *myf5*^+^, a gene known to be also expressed in committed skeletal muscle precursors ([@B19], [@B20]). The developmental origin of the beige adipocyte remains to be elucidated. The whole-body NST will have contributions from both classical brown and beige adipocytes.

It is now beyond doubt that BAT is present in adult humans and plays a role in NST ([@B3]). BAT activity can be detected by ^18^F-fluorodeoxyglucose (^18^F-FDG) uptake using PET--CT ([@B2], [@B4], [@B5]). Retrospective analysis of populations that have undergone PET--CT examination indicates that the prevalence of BAT varies between 1 and 5%. For example, one study on 4011 asymptomatic individuals (\<5% obese subjects) showed that BAT prevalence is 5% in female and 1.3% in male ([@B21]). The BAT-positive subjects had lower body mass index (BMI), less visceral and subcutaneous fat areas, lower fasting glucose and TG levels, and increased HDL cholesterol concentrations compared to the BAT-negative subjects. Similar results were reported for 56 healthy volunteers ([@B22]), and for cancer patients ([@B2], [@B23]). The inverse correlation between BAT activity and BMI was further confirmed in non-diabetic subjects over a wide range of body compositions (BMI ranging from 22 to 48 kg/m^2^) ([@B4], [@B24]--[@B27]). A recent retrospective analysis of ^18^F-FDG uptake data (analysis of the neck regions of two relatively large cohorts of individuals) reports that the average body weight of BAT-positive individuals is approximately 5 kg lower compared to that of BAT-negative subjects ([@B21], [@B23]).

Using a combination of MRI and molecular analysis, Enerbäck's group clearly demonstrated that iBAT in human infants consists of classical brown adipocytes ([@B15]). However, the molecular signature of brown adipocytes isolated from the neck regions of adult humans resembles that of the rodent beige phenotype rather than classical brown adipocytes ([@B15], [@B28]--[@B31]). What causes the BAT phenotype transformation between infant and adult humans is not understood. It is conceptually important to unravel the function, regulation, and differentiation of beige and classical brown adipocytes in order to be able to pharmacologically enhance thermogenesis in humans. For example, if the adipocytes with various white and beige appearances in adult human neck region are, in fact, simply dormant brown adipocytes, they may be readily re-activated by cold or sympathomimetics. In addition, it is important to understand the translational aspects of BAT biology, i.e., whether the same or different pharmacological agent(s) will show desirable effects in preclinical animal species and man?

Bat and Metabolic Significance {#S3}
==============================

The contribution of BAT to whole-body metabolism in rodents has recently been examined using tools such as radioactive tracers and PET--CT imaging. Bartelt et al. showed that BAT is the major site of triglyceride-rich lipoprotein (TRL) clearance during acute cold exposure ([@B32]). Cold exposure also dramatically increased the glucose disposal to BAT tissue. The remarkable capacity of BAT to take up substrates is illustrated by the ratio of BAT mass to the total glucose and TG uptake by BAT compared to that of other major organs in mice under cold challenge. Labbe et al. extended this observation through PET--CT analysis of the rate of substrate flux and oxidation in the iBAT of both warm- and cold-adapted rats ([@B33]). The rate of glucose uptake into iBAT was relatively low at 27°C but increased 10-fold upon acute cold exposure and increased 46-fold after cold acclimation at 10°C. Similarly, NEFA levels rose 6-fold upon acute cold exposure, and \~100-fold after cold acclimation. The metabolic activity of the iBAT reached levels similar to that of heart and liver after 6 h of cold exposure. In spite of these results, it should be kept in mind that although BAT glucose uptake per unit volume of tissue is important, the bulk of glucose turnover during cold exposure is mediated by skeletal muscle metabolic activation even when shivering is minimized ([@B7]).

It is more challenging to determine the specific contribution of beige adipocytes to whole-body metabolism. Bartelt et al. showed that acute cold exposure also increases TRL uptake in inguinal WAT (iWAT), but to a smaller extent compared to iBAT ([@B32], [@B34]). Seale's group reported an aP2-PRDM16 transgenic mouse that exhibited a highly favorable metabolic phenotype, in which iBAT remained unchanged but with extensive browning in iWAT. This suggests that beige adipocytes may contribute to the overall metabolic phenotype observed in this mouse ([@B35]).

On the whole-body level, Reitman's group dissected the relative contributions of cold-induced, diet-induced, and physical activity-associated EE in mice in relation to the basal metabolic rate (BMR) at various temperatures ([@B36]). This work clearly illustrated that at 22°C, the temperature at which most reported metabolic studies have been conducted, mice expend a relatively large amount of energy to generate heat (120% of BMR). Adult humans, on the other hand, live in or near their thermoneutral zone, with a relatively small contribution from adaptive thermogenesis to EE (5% of BMR) ([@B11]). Interestingly, in mice housed at thermoneutrality (30--32°C), the relative contributions of BMR, diet, physical activity, and adaptive thermogenesis in mice to overall EE are reported to be \~60, 12, 25, and 0%, respectively ([@B36]). These figures are very similar to the relative contributions seen in humans with low activity levels, and might represent experimental conditions more suitable for translational research in this field. The EE increase in relation to external temperature is conceptually depicted in Figure [2](#F2){ref-type="fig"} (not scaled to real data).

![**Adaptation of EE and adipose tissue morphology and function to the changes of environmental temperature in the mouse**. Sympathetic tone to adipose tissue plays an important role in this process. Most current published rodent studies are conducted at temperatures below the thermoneutral zone, while humans typically live near the thermoneutral zone. For adequate translation between species, rodent studies should be performed under thermoneutral conditions.](fendo-06-00174-g002){#F2}

Numerous studies that address the role of human BAT activation and its quantitative impact on whole-body metabolism have been published. Based on the heat production capacity of mouse BAT, Rothwell and Stock proposed in the 1980s that 40--50 g of BAT, if maximally activated, could account for 20% of daily EE in human ([@B37]). More recently PET--CT measurements estimated the average active BAT volume in healthy humans to be 137 cm^3^, corresponding to a conservative estimate of around 50 g BAT mass ([@B11]). Virtanen et al. estimated the EE of human BAT to be 55 W/kg ([@B5]) based on the rate of glucose uptake during cold exposure, as measured by dynamic PET--CT. These conservative estimates suggest that the EE of fully activated BAT could amount to 2--5% of BMR. Recent cold exposure experiments confirmed that the cold-induced NST-associated increase in EE accounts for 0--15% of BMR ([@B11]). Using a human body-composition model ([@B38]), we further extrapolated that a 4% increase of BMR could lead to a 3% bodyweight reduction per year, assuming that the effects are sustained. A key assumption in such an extrapolation is that functional tolerance can be avoided ([@B39]). In support of this assumption, some pieces of evidence suggest that increased thermogenesis is not always fully compensated for and negated by an increase in food intake, for reasons that are not fully understood ([@B40]).

Cypess et al. recently reported a 13% increase in BMR as a result of BAT activation upon administration of an acute dose of the β~3~-AR agonist mirabegron ([@B41]). Again, assuming that this BMR increase could be sustained upon chronic treatment, modeling suggests that this could potentially lead to an 8% bodyweight loss per year in BAT-positive healthy men. Besides potential functional tolerance, it remains uncertain if chronic β-AR-mediated stimulation of BAT is possible without encountering the side effects often associated with β-AR agonists.

Bodyweight reduction has been shown to have positive effects not only on preventing the progression of pre-diabetes to diabetes, but also leads to a reduction of hemoglobin A1c (HbA1c) ([@B42]). More recently, Hanssen et al. showed that 10-day cold acclimation in obese T2D patients could increase BAT activity, which was in turn associated with a reduction of BAT TG content and increased EE ([@B43]). One very encouraging observation is the 43% improvement of glucose infusion rate during a clamp study. Importantly, the improvement in insulin sensitivity of both adipose and skeletal muscle appeared before any bodyweight change could be seen ([@B43]). As indicated by Hanssen et al., the cold-induced improvement in insulin sensitivity exceeds that which was observed after long-term exercise training. To place this in a pharmacological context, this improvement in insulin sensitivity is similar in extent to that seen after 2-week treatment with dapagliflozin (Farxiga/Forxiga), which affords an 18% improvement in tissue glucose disposal ([@B44]).

Functional Brown/Beige Adipocytes {#S4}
=================================

The remarkable metabolic capacity of classical brown adipocytes in the activated state has been well characterized using rodent brown adipocytes. Functional characterization of beige adipocytes from the inguinal adipose tissue of mice or differentiated beige adipocytes from human adipose stem cells suggests that these cells are functionally similar to classical brown adipocytes ([@B45], [@B46]). The developmental origin of brown and beige adipocytes is currently an area of intense research and has been extensively reviewed elsewhere ([@B47], [@B48]).

Uncoupling of the mitochondrial transmembrane proton gradient in brown adipocytes in order to generate heat in response to cold is a complicated but well-orchestrated event. The key metabolic and signaling pathways in the brown or beige adipocyte are summarized in Figure [3](#F3){ref-type="fig"}. To be able to carry out this function, brown adipocytes need to be equipped with a complex machinery that is able to (i) signal through norepinephrine (NE) or other catecholamines via β-ARs, (ii) generate intracellular FFAs through hydrolysis of TGs from lipid droplets (lipolysis), and (iii) uncouple the ATP-generating process via UCP1 activation ([@B13], [@B49]). Chronically, cold challenge leads to a recruitment process in which cell proliferation, mitochondrial biogenesis, and angiogenesis are enhanced. Given the broad range of cellular processes that are involved in these events, it is not surprising that large numbers of genes/factors have been described to regulate the differentiation and function of brown and beige adipocytes ([@B9], [@B34]).

![**Diagram showing key metabolic and signaling pathways in brown or beige adipocytes**.](fendo-06-00174-g003){#F3}

The β~3~-AR has emerged as a leading molecular target for the activation of brown or beige adipocytes ([@B18], [@B41]). Rodent and human adipose tissue display different β-AR expression profiles. ([@B50]--[@B53]). In mouse, the β~3~-AR is highly expressed in both BAT and WAT with several-fold higher abundance than the β~1~-AR, whereas in the adult human, the β~3~-AR is only expressed in BAT. In human WAT, β~1~-AR has been reported to be 50-fold more abundant than β~3~-AR ([@B52]). The β~3~-AR subtypes also differ in their potency toward various ligands, G-protein coupling, and desensitization. The binding affinity of NE to β~3~-AR was reported to be in the low micromolar range, while the potency for cAMP accumulation is in the low nanomolar range when measured in intact cells, suggesting that the coupling efficacy to adenylyl cyclase of β~3~-AR was higher than that of β~1~-AR ([@B52], [@B54]). In addition, β~1~-AR desensitizes more rapidly than β~3~-AR upon exposure to agonists. This led to the hypothesis that β~1~-AR may mediate the NE response to low levels of sympathetic stimulation. On the other hand, the activation of β~3~-AR may require higher levels of sympathetic stimulation, but once activated this receptor is likely to deliver a more sustained effect ([@B52]). It is important to note that circulating NE levels are generally in the low nanomolar concentration range, and it is likely that NE concentrations at the synaptic clefts will be much higher during cold response, providing sufficiently high local concentrations in BAT to enable local activation of β~3~-AR in spite of the low plasma concentration. Recently, several studies have shown that systemic administration of adrenergic activators, such as isoproterenol (ISO) and ephedrine, fail to elicit BAT activation in man ([@B55]--[@B57]). To properly interpret these clinical data, it is crucial to understand if the plasma concentrations of the adrenergic agonists used reached a sufficiently high concentration to enable activation of lipolysis and thermogenesis in human BAT.

Norepinephrine-mediated β-AR activation results in an increased intracellular cAMP concentration, which in turn stimulates lipolysis in brown adipocytes via activation of the protein kinase A pathway. Lipolysis is a stepwise process with different enzymes acting at each step: TGs are hydrolyzed by desnutrin/adipose triglyceride lipase (ATGL) to form diacylglycerol (DAG). DAG is then hydrolyzed by hormone-sensitive lipase (HSL) to monoacylglycerol and, subsequently glycerol, with a fatty acid released at each stage. Intracellular FFAs are the direct activators of UCP1 ([@B58]). In humans, the BAT radiodensity (which is indicative of intracellular TG stores) is inversely correlated with NST, strongly suggesting that depletion of intracellular TG occurs during cold exposure. In rats, inhibition of lipolysis by nicotinic acid-mediated GPR109a agonism significantly reduced the oxidative capacity of iBAT in response to cold, again suggesting a key role for lipolysis in UCP1-mediated thermogenesis ([@B33]). Additionally, adipose tissue-specific knockout of ATGL led to the formation of "whitened" brown adipocytes and resulted in impaired lipolysis and defective thermogenesis in BAT ([@B59]--[@B62]).

The brown adipocytes' cold-depleted energy stores are replenished by *de novo* lipogenesis and glycogen synthesis, which requires cellular uptake of circulating glucose and FFAs (derived either from TRLs or from lipolysis in WAT). In brown adipocytes, glucose uptake is mostly mediated by glucose transporter 1 (GLUT1) and glucose transporter 4 (GLUT4) and subsequently stored as glycogen or converted to lactate through anaerobic glycolysis. As shown in Figure [3](#F3){ref-type="fig"}, FFAs are transported into the cell by cluster of differentiation 36 (CD36) and TGs are subsequently synthesized through re-esterification by a series of enzymes, including glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol O-acyltransferases (DGATs) ([@B49]). The process of recruitment of new brown or beige adipocytes and the maintenance of mature adipocyte function during acute and chronic cold acclimation are subject to complex transcriptional and hormonal regulation, for example, by PPARγ, bone morphogenic proteins (BMPs), the thyroid axis, and FGF21. These regulatory mechanisms have been extensively reviewed elsewhere ([@B8], [@B47], [@B48], [@B63]).

The functional activity of BAT is reduced by chronic warm acclimation, old age, obesity, and diabetes. Rodent models of genetic deficiency of leptin (*ob/ob*, *db/db*, and obese *fa/fa* rats) are cold sensitive, and their brown adipocytes have a white adipocyte appearance with reduced expression of UCP1 protein ([@B64], [@B65]). Old age and lack of cold challenge also reduce the thermogenic activity of the brown adipocytes ([@B66]). Brown adipocytes isolated from guinea pigs housed at 30°C appear unilocular, although these cells appear to retain their brown adipocyte identity and are able to respond to NE with a robust increase of thermogenesis, which is not the case for adipocytes isolated from WAT ([@B67]). In humans, BAT activity is inversely correlated with age, fat mass, and BMI. Insulin-stimulated glucose uptake is also compromised in the BAT of diabetic individuals ([@B68]). Recent reports that both chronic cold acclimation and weight loss can enhance BAT activity in humans are encouraging ([@B27], [@B69], [@B70]), indicating that reduced BAT function may be restored. In this respect, adipocytes or adipose precursor cells are highly plastic and able to adapt to the functional needs, as has been shown in rodent using lineage tracing experiments ([@B71]).

Thiazolidinediones {#S5}
==================

The TZDs \[represented by rosiglitazone (Avandia) and pioglitazone (Actos)\] are a chemical class of PPARγ agonists used as insulin sensitizers for the treatment of T2D ([@B72]). The primary site of action of the TZDs is adipose tissue, where they improve several functional aspects, including the uptake and storage of plasma NEFA. They also increase FFA mobilization under fasting conditions and enhance postprandial suppression of FFA mobilization by insulin ([@B73]).

Thiazolidinediones have been shown to increase UCP1 expression and BAT mass in rodents. Rosiglitazone has been shown *in vitro* by several laboratories to induce UCP1 in rodent brown adipocytes and differentiated adipose stem cells ([@B74]--[@B77]). In addition, chronic treatment of human subcutaneous adipose stem cells with rosiglitazone upregulated several components of the mitochondrial electron transport chain, which is consistent with what has been observed in human ([@B78]). The UCP1 protein in human adipocytes differentiated *in vitro* in the presence of rosiglitazone is only functional when cells have been allowed to differentiate for a longer time than is typically reported in mouse studies ([@B45]). Although TZDs have the ability to recruit the "browning program" in both mouse and human adipocytes, the thermogenic capacity of UCP1-expressing cells cannot be unleashed without subsequent activation (e.g., by β-AR agonists). An increase in the oxygen consumption rate (OCR) of human adipocytes differentiated *in vitro* in the presence of rosiglitazone could only be observed when the cells were stimulated with isoproterenol or in the presence of exogenously provided FFAs. The increase of OCR in these beige cells is completely UCP1 dependent, as UCP1 knock-down abolishes the effect ([@B45]).

Various *in vivo* rodent models of insulin resistance have been used to show that the TZDs increase UCP1 mRNA in iBAT and overall iBAT weight. However, this is not associated with a subsequent increase in thermogenesis or whole-body EE. In addition, TZD treatment leads to the brown adipocytes becoming lipid filled ([@B79]--[@B81]). This led to the hypothesis that obese and diabetic animals or humans could first be primed by a PPARγ agonist to expand the BAT capacity, followed by its activation via a β-AR agonist. This concept was tested pre-clinically in *ob/ob* mice by pre-treating with a PPARγ agonist (COOH, a non-TZD PPARγ agonist) followed by treatment with the β~3~-AR agonist CL-316,243. Synergistic effects on EE and bodyweight reduction were indeed observed in this single study ([@B82]). However, a later study using rosiglitazone followed by acute cold exposure failed to reproduce these effects ([@B83]). A possible explanation for the lack of increased EE in spite of increased TG storage, UCP1 expression and BAT mass induced upon PPARγ activation by rosiglitazone ([@B84]) may be the downregulation of β~3~-AR and iodothyronine deiodinase type II (DIO2) expression caused by TZD treatment ([@B85], [@B86]). In addition, as COOH belongs to a different structural class of PPARγ agonists to the TZDs, it is not unlikely that different outcomes could be observed between the two compounds. In humans, 12 weeks of pioglitazone treatment has been shown to generate a small increase in UCP1 mRNA levels in subcutaneous adipose tissue ([@B87]). However, combined pioglitazone and ephedrine treatment for 12 weeks in obese human subjects failed to deliver significant bodyweight reduction ([@B88]).

When comparing the observed outcomes of studies employing PPARγ agonists, it must be kept in mind that even structurally closely related compounds may exhibit very different PPARγ-dependent pharmacodynamic profiles. This is, in part, due to ligand-dependent modulation of the PPARγ protein that leads to recruitment of different coactivator and corepressor proteins, in turn resulting in a unique transcriptional profile for each compound ([@B89]). Since the identification of PPARγ as the molecular target of the TZDs ([@B90]), significant effort has been invested by the pharmaceutical industry in PPARγ agonist drug discovery ([@B91]--[@B96]) albeit largely without commercial success ([@B97]). The availability and high throughput of PPARγ LBD-based ligand binding assays and chimeric PPARγ--GAL4 reporter gene/transactivation assays enabled the generation of many highly potent, structurally diverse, selective PPARγ full and partial agonists. Despite this, since the launch of pioglitazone and rosiglitazone, no new selective PPARγ agonists have survived clinical testing and remain on the market, mainly due to preclinical and clinical safety issues ([@B98]--[@B101]). The central role of PPARγ in adipose biology has, however, not diminished due to these failures and PPARγ remains an attractive but challenging drug target.

The lack of translation between *in vitro* receptor binding and the functional (both *in vitro* and *in vivo*) effects of the compounds and inter-species differences in PPARγ biology are considered major obstacles in this field. This is due to a number of factors, including the combinatorial nature of the activation of the PPARγ:RXR heterodimer ([@B102], [@B103]), subtle differences in coactivator/corepressor recruitment between superficially related compounds ([@B104]--[@B107]), ligand effects on the extent of posttranslational modifications ([@B108], [@B109]), and non-transcriptional effects of the ligands ([@B72]). This suggests that a reductionist approach to PPARγ agonist discovery based on the use of isolated protein domains and chimeric reporter gene assays is unlikely to provide compounds with the desired functional or clinical outcome.

Since the "traditional" approach of optimizing receptor binding and agonist potency has not borne fruit, a radical change in the preclinical approach to PPARγ drug discovery is needed in order for the functional potential (for example, browning of WAT) of small-molecule PPARγ activation to be realized. For example, the application of phenotypic screening in relevant cell systems \[i.e. primary human cells ([@B110])\] is one approach to frontload the functional assessment of compounds, with traditional *in vitro* assessment of PPARγ activity included in a secondary wave of assays. In addition, the recent widespread availability of omics techniques (such as *RNA*omics and proteomics) makes the preclinical identification of PPARγ agonists with a desirable functional profile a realistic prospect. A combination of such approaches avoids focus on a single receptor-dependent pathway or mechanism and allows pleiotropy to be accounted for. However, whether the perceived target-related risk associated with PPARγ agonism is considered acceptable in proportion to the potential commercial viability of a safe PPARγ agonist remains to be seen.

Beta-3 Adrenergic Receptor {#S6}
==========================

Several sympathomimetic β~3~-AR agonists that selectively stimulate rodent brown and white adipocyte lipolysis were discovered from the mid-1980s onward (e.g., BRL-37344, CL-316,243, and CGP-12177A) ([@B50], [@B51], [@B111]). Early optimization of these compounds was mostly performed in rodent tissue or cell models, as the human β~3~-AR was not cloned until 1989 ([@B112]). The compounds showed potent anti-obesity and anti-diabetic effects in rodent models of obesity and diabetes, but none of these compounds advanced beyond the clinical phase II due to lack of efficacy. Specifically, compounds optimized using rodent β~3~-AR did not effectively translate to human. Several β~3~-AR agonists were synthesized and evaluated after the cloning of human β~3~-AR cDNA ([@B113]). A summary of studies investigating the effect of β~3~-AR agonism on EE in man is given in Table [1](#T1){ref-type="table"}. Note that many binding and adenylyl cyclase activity assays were performed using isolated membrane preparations, returning β~3~-AR binding affinities in the micromolar range for the compounds tested. Lower potencies (in the nanomolar range) have been reported for the same compounds when measured in whole-cell assays (cAMP, lipolysis, or respiration) ([@B52]), suggesting a G-protein coupling efficiency for the β~3~-AR that is only captured in a whole-cell context.

###### 

***In vitro* properties of β~3~-adrenergic receptor agonists that have been tested in humans, and their effect on energy expenditure in man**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PHYSICAL AND PHARMACOKINETIC PROPERTIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  **Compound name(s) and chemical structure**   **CL-316,243**\                                                                                                                                                                      **ZD7114**\                                                                                                            **ZD2079 (Talibegron)**\                                                                         **L-796568**\                                                                                                                           **TAK-677 (Rafabegron)**\                                         **Mirabegron (YM-178)**\
                                                ![](fendo-06-00174-i001.jpg)                                                                                                                                                         ![](fendo-06-00174-i002.jpg)                                                                                           ![](fendo-06-00174-i003.jpg)                                                                     ![](fendo-06-00174-i004.jpg)                                                                                                            ![](fendo-06-00174-i005.jpg)                                      ![](fendo-06-00174-i006.jpg)

  **MW (g/mol)**                                466.8 (Na~2~ salt), 421.8 (free acid)                                                                                                                                                418.5                                                                                                                  315.4                                                                                            624.7                                                                                                                                   402.9 (free acid)                                                 396.5

  **clogP**                                     −1.4                                                                                                                                                                                 2.1                                                                                                                    −0.3                                                                                             5.3                                                                                                                                     0.7                                                               1.3

  **Human β~3~ potency/TE**                     EC~50~ 1.15 μM/0.63[^a^](#tfn1){ref-type="table-fn"} ([@B114])                                                                                                                       *K*~act~ 20 nM (for ZD201651, the major active metabolite) ([@B115])                                                   K~act~ 191 nM/0.91[^a^](#tfn1){ref-type="table-fn"} ([@B116])[^b^](#tfn2){ref-type="table-fn"}   3.6 nM/0.94[^a^](#tfn1){ref-type="table-fn"} ([@B117])                                                                                  EC~50~ 0.062 nM/1.16[^a^](#tfn1){ref-type="table-fn"} ([@B118])   22 nM/0.8[^a^](#tfn1){ref-type="table-fn"} ([@B119])

  **Rodent β~3~ potency/TE**                    Rat *K*~i~ 1 μM, *K*~act~ 0.71 nM/1[^a^](#tfn1){ref-type="table-fn"} in β~3~ overexpressing CHO cells ([@B111])                                                                      --                                                                                                                     --                                                                                               --                                                                                                                                      0.016 nM/1.1[^a^](#tfn1){ref-type="table-fn"} (rat cAMP)          --

  **Fold selectivity β~3~:β~2~:β~1~**           1:228:96 Based on CHO data ([@B114]). Reported as an antagonist @ β~1~ and β~2~ ([@B120])                                                                                            --                                                                                                                     --                                                                                               1:667 (partial):1333 (partial)                                                                                                          1:209 (partial):1032 (partial)                                    1:\>446 (partial):\>446 (partial)

  ***T*~1/2~/%F**                               16 h/10% (human)[^c^](#tfn3){ref-type="table-fn"}                                                                                                                                    --                                                                                                                     --                                                                                               \>8 h/17% (rat)                                                                                                                         --                                                                --

  **PHARMACODYNAMICS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Population**                                Healthy young lean males ([@B124])                                                                                                                                                   Obese men and women with BMI 27--39 kg/m^2^ ([@B115])                                                                  Obese men and women with BMI 27--39 kg/m^2^ ([@B115])                                            Healthy overweight to obese men ([@B121])                                                                                               Obese men and women, mean BMI 33.9 kg/m^2^ ([@B122])              Healthy male subjects with detectable BAT ([@B41])

  **Administration**                            1.5 g/day for 8 weeks (*n* = 10)                                                                                                                                                     150 mg/day for 2 weeks (*n* = 5)                                                                                       1.2 g/day for 2 weeks (*n* = 9)                                                                  375 mg/day for 28 days (*n* = 10)                                                                                                       0.5 mg BID for 29 days (*n* = 22)                                 200 mg acutely (*n* = 12; crossover study)

                                                Placebo (*n* = 4)                                                                                                                                                                    300 mg/day for 2 weeks (*n* = 8) Placebo (*n* = 22)                                                                    Placebo (*n* = 8)                                                                                Placebo (*n* = 10)                                                                                                                      Placebo (*n* = 4)                                                 

  **Exposure**                                  30 ± 11 nM (steady-state *C*~min~)                                                                                                                                                   --                                                                                                                     --                                                                                               77 ± 30 nM (steady-state *C*~min~)                                                                                                      24 ± 13 nM (at *t* = 2 h)                                         781 ± 184 nM (*C*~max~)

  **Fold *in vitro* EC~50~**                    \<0.1                                                                                                                                                                                --                                                                                                                     --                                                                                               \>20                                                                                                                                    \>1000                                                            \>30

  **BAT activity**                              --                                                                                                                                                                                   --                                                                                                                     --                                                                                               --                                                                                                                                      --                                                                Significant increase in BAT glucose uptake, from 1 to 130 mL × SUV~mean~ × g/mL

  **Energy expenditure**                        24-h EE after 8 weeks did not differ from baseline                                                                                                                                   No effect on 24 h EE                                                                                                   Trend for stimulatory effect on 24-h EE (2.4%)                                                   Mean change in 24-h EE upon treatment did not differ significantly between treated and placebo                                          Slight increase (\~50 kcal/day) in 24-h EE at the highest dose    Increased resting metabolic rate by 203 ± 40 kcal/day (+13%; *p* = 0.001)

  **Fasting plasma insulin**                    Trend toward decrease                                                                                                                                                                --                                                                                                                     --                                                                                               No significant change                                                                                                                   No significant change                                             Significant increase from 5.06 (3.56--6.19) to 7.61 (6.90--8.66) (μU/mL)

  **Other observations**                        No change in body weight or body composition. Increase in insulin action, decrease in 24-h RQ implying 23% increase in fat oxidation. No β~1~ or β~2~ side effects (bp/heart rate)   Acid metabolite also a β~3~ partial agonist. Increases UCP1 expression in dogs (2-week study 10 mg/kg BID) ([@B123])   Trend for increase in spontaneous physical activity                                              No major lipolytic or thermogenic effect but lowered triacylglycerol concentrations. No β~1~/β~2~ side effects (heart rate or tremor)   No effect on 24-h RQ or fat oxidation                             BAT metabolic activity was a significant predictor of the changes in RMR. Heart rate and systolic BP increased
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*MW, molecular weight; TE, target engagement; EE, energy expenditure; RQ, respiratory quotient*.

*^a^Isoproterenol response defined as 100%*.

*^b^Primary reference refers to an, at that time, yet unpublished paper from ICI*.

*^c^Claimed to be a full agonist, but only 80% TE in in vitro assay*.

Most early human trials of β~3~-AR agonists used bodyweight reduction as a clinical endpoint, to be achieved through increased EE. Data on BAT activation and metabolic parameters are scarce, with the exception being for the CL-316,243 study ([@B124]). In this study, treatment of lean healthy men for 4 weeks did not increase EE, but resulted in a 45% increase of insulin-mediated glucose disposal and a reduced 24-h respiratory quotient (24-h RQ), indicating enhanced fat oxidation. Intriguingly, CL-316,243 significantly increased fasting FFA levels in parallel with improved insulin action. These data are in line with recently published improved glucose infusion rates in T2D patients after 10 days of mild cold exposure ([@B43]). In both cases, improved insulin action preceded any significant weight loss. This improved action of insulin may be due to partitioning of FFAs toward BAT, which in turn reduces the fatty acid burden on other metabolic tissues (see Figure [1](#F1){ref-type="fig"}). Indeed, improved glucose uptake was seen in the skeletal muscle of T2D patients after cold exposure ([@B43]).

Similarly to CL-316,243 treatment, chronic dosing of the β~3~-AR agonists ZD7114 and ZD2079 did not significantly increase EE, although the latter compound showed a tendency toward a non-statistically significant increase of 2% ([@B115]).

Data have been reported for both acute and chronic dosing of β~3~-AR agonist L-796568 in overweight to obese men. Acutely, van Baak et al. ([@B125]) reported a significant increase (8%) in EE after 4 h for the highest dose used. However, no average increase was observed over the period of observation, 0--4 h. Chronic dosing of L-796568 for 4 weeks did not result in any significant change in EE ([@B121]). The authors discuss possible reasons for this lack of effect, e.g., declining plasma exposure levels over time, insufficient agonist-induced BAT proliferative capability of β~3~-AR-responsive tissues in humans during chronic stimulation, potential downregulation of β~3~-AR receptors, or other functional feedback. We believe that the small effect on EE observed in the acute study is another reason.

A chronic β~3~-AR agonism study (using TAK-677) in obese humans with no observed effect on EE or diabetic parameters was reported by Redman et al. ([@B122]). Whether BAT activation truly occurred after administration of compound was not carefully assessed in this study, which makes data interpretation challenging.

In contrast to the above-mentioned β~3~-AR agonism studies, Cypess et al. recently reported a \~13% increase in resting metabolic rate (RMR) upon acute treatment with high doses of β~3~-AR agonist mirabegron ([@B41]). In this study, healthy young male subjects with detectable BAT were selected in order to provide proof of concept (PoC) for β~3~-AR agonist-mediated BAT activation. Importantly, it was found that BAT metabolic activity was a significant predictor of the changes in RMR. This study also reports a weak correlation between cold- and drug-induced detectable BAT activities. Generally, such data from the same individuals are important to help put the large quantity of cold-induced BAT activation data into a drug-discovery context. It remains to be investigated if the reported energy-expenditure effect is sustained upon chronic dosing and if the efficacy of mirabegron will persist in females and other patient subpopulations, such as those with different ages and BMIs.

The failure of β~3~-AR agonists to show clinical effects on weight loss decreased interest in the mechanism as a means of treating the metabolic syndrome. However, the recent rediscovery of BAT in adult humans as well as the demonstration of functional activation of BAT by a β~3~-AR agonist may lead to a resurgent interest in β~3~-AR agonists for the treatment of metabolic disorders. The observation that improved insulin action preceded any significant weight loss upon β~3~-AR agonist treatment is particularly encouraging.

Clearly, important questions remain unanswered with respect to the role of the β~3~-AR and the clinical profile of β~3~-AR agonists. In order to make significant progress in β~3~-AR drug discovery, the lack of translation from rodent to human (i.e., receptor expression and functional differences) and from *in vitro* to *in vivo* for the human setting needs to be resolved. The clinically assessed β~3~-AR agonists exhibit structural and physicochemical property diversity; however, clinical plasma exposures relative to EC~50~ are similar for the chronic and acute studies (Table [1](#T1){ref-type="table"}), and activation of BAT would therefore be expected in the chronic studies. The lack of effect on EE observed in the chronic studies may either be due to not measuring a mechanism-relevant clinical endpoint or that the patients recruited lacked sufficient BAT to lead to an effect on overall EE. The activation of pre-existing BAT by β~3~-AR agonists may require a personalized healthcare approach, unless combined with a compound or mechanism to expand the BAT depot.

Finally, cardiovascular side effects have been associated with β~3~-AR agonist treatment, usually attributed to insufficient selectivity toward the β~1~- and β~2~-ARs. However, the *in vitro* functional activity of many of the clinical compounds assessed does not explain the increase in heart rate observed -- several of the compounds are functional β~1~-AR antagonists (β~1~-AR blockers), and as such could be expected to have the opposite effect to that clinically observed. The complex nature of AR biology needs to be further investigated if this mechanism is to be reconsidered as a means of activating BAT.

Fibroblast Growth Factor 21 {#S7}
===========================

Fibroblast growth factor 21 (FGF21) is a member of the endocrine FGF 19/21/23 family. FGF21 protein is expressed in liver, pancreas, and adipose tissue and is regulated by fasting, ketogenic diet, low protein diet, PPARγ, and PPARα activation as well as glucagon action ([@B126]). It acts through binding to a cell-surface receptor complex composed of conventional FGF receptors (FGFR1c/2c/3c) and the co-factor β-Klotho, leading to activation of FGF receptor substrate 2α and ERK1/2 phosphorylation. While FGF receptors are ubiquitously expressed, β-Klotho expression is restricted to a few tissues, including BAT, WAT, and liver ([@B127], [@B128]), which are the main sites of FGF21 action. When administered pharmacologically, FGF21 enhances EE and insulin sensitivity, reduces bodyweight, glucose, and lipids, and thus has the potential to be used for treatment of the metabolic syndrome via multiple mechanisms ([@B129]--[@B131]).

Functional enhancement of existing BAT and recruitment of beige adipocytes have been hypothesized to be the mechanism behind the EE increase, bodyweight loss, and improved glucose and lipid homeostasis induced by FGF21. FGF21 expression is increased in BAT upon cold challenge ([@B132], [@B133]). Adipose-derived FGF21 acts in an autocrine/paracrine manner to increase expression of UCP1 and other thermogenic genes, such as *PGC1*α, *PRDM16*, *BMP8b*, and *DIO2* in iBAT and iWAT ([@B134], [@B135]). In neonates, FGF21 expression in liver is increased by suckling, which occurs via activation of PPARα, leading to induced BAT thermogenesis ([@B136]).

Attempts have been made to directly assess the contribution of BAT and beige adipocytes to FGF21-mediated effects. Surgical resection of iBAT in two different mouse models showed that FGF21-mediated EE increase and bodyweight reduction were retained ([@B137], [@B138]). However, one of the studies showed that several beige adipocyte markers, including *PPARγ*, *PRDM16*, *PGC1α*, and *CIDEA* tended toward upregulation in subcutaneous adipose tissue, and perigonadal adipose weight also was reduced ([@B138]). The authors propose that residual BAT and beige adipocytes may have compensated for the loss of iBAT. Recently, the role of UCP1 in mediating the pharmacological effects of FGF21 was assessed by treating UCP1 knockout (UCP1 KO) mice with either recombinant FGF21 or FGF21 fused with fragment crystallizable region (Fc-FGF21) ([@B139], [@B140]). Surprisingly, several FGF21-mediated effects were largely retained in the absence of UCP1. Again, compensatory mechanisms seem to be activated in UCP1 KO mice treated with recombinant FGF21. In FGF21-treated UCP1 KO mice, reduced food intake offset the decrease in EE and resulted in a similar bodyweight reduction to that observed in FGF21-treated wild-type mice. In addition, genes regulating fatty acid metabolism were upregulated in liver and epididymal adipose tissue, suggesting that FGF21 recruits UCP1-independent pathways in these tissues to compensate for the lack of UCP1. An intriguing observation was a two- to threefold increase in FGF21 secretion in iBAT when UCP1 KO mice were challenged by cold, suggesting that FGF21 may be one of the factors that recruit alternative thermogenic mechanisms when iBAT/UCP1 fails to generate heat. It should be noted that many previous publications have showed remodeling of the WAT in UCP1 KO mice, and that alternative thermogenic mechanisms have been discussed ([@B141], [@B142]).

In spite of the attractive metabolic effects of FGF21, development of FGF21-based therapeutics has encountered several technical challenges, including short *in vivo* half-life and poor biophysical properties of FGF21 protein (e.g., it is prone to aggregation). To date, three different analogs of FGF21 have advanced to concept testing in human: ([@B130], [@B143], [@B144]) (i) LY2405319 (an aggregation-resistant FGF21 analog), (ii) PF-05231023 (FGF21 linked to a Fab fragment of a scaffold antibody), and (iii) ARX-618 (PEGylated FGF21). For both LY2405319 and PF-05231023, the effects on TG (close to 50% reduction in 28 days), LDL cholesterol, and HDL cholesterol were substantial and bodyweight reduction was significant. However, the failure of FGF21 analogs to achieve clinically meaningful glucose-lowering effects was unexpected, and the mechanism behind this remains to be understood. Recently, Genentech reported a bispecific monoclonal antibody agonist that binds to both FGFR1c and β-Klotho, with sustained effects on NST, EE, and bodyweight over a 35-day period after a single administration to diet-induced obese mice ([@B145]). The effects on glucose and lipids were similar to those observed after administration of recombinant FGF21, and mostly attributed to peripheral FGF21 action as CNS exposure of the antibody was reported to be minimal. Together, these data further support the importance of BAT function in FGF21 action. As for the β~3~-AR agonist story, it may be important for future clinical concept testing to assess BAT recruitment/activation in order to understand if sufficiently high FGF21 levels have been achieved in patients. In addition, it is critical to constantly monitor potential safety concerns of this treatment principle in all studies, including bone density, growth hormone resistance, and female fertility.

Perspectives {#S8}
============

The understanding of BAT physiology has increased rapidly in recent years. Data generated in both rodents and humans in cold/warm acclimation studies suggest that both BAT and beige adipocytes demonstrate recruitability and plasticity, which opens the door to pharmacological intervention. As obese and T2D patients are likely to have reduced BAT function, in order to realize the full potential of NST, it may be necessary to first restore the function of "whitened" brown or beige adipocytes before activation (Figure [2](#F2){ref-type="fig"}). In this respect, future studies using rodent models require consideration of external temperature in order to more closely mimic human physiology. Cold acclimation for a short duration in obese and diabetic humans indicates that it is possible to enhance BAT activity and achieve an improved metabolic profile before significant bodyweight reduction occurs. The improved insulin action in the absence of bodyweight change seen in the 4-week treatment of healthy individuals by CL-316,243 ([@B124]) suggests that restoration of BAT function may at least lead to improved metabolic control in patients with T2D. Acute treatment of BAT-positive human subjects with the β~3~-AR agonist mirabegron resulted in a significant increase in EE. If this effect is sustained upon chronic dosing and without eliciting cardiovascular side effects, this mechanism may finally lead to significant weight loss.

PPARγ remains an interesting target for the recruitment of BAT or beige adipocytes, although discovery of a compound that does not impair the adrenergic sensitivity or thyroid function of the adipocyte is extremely challenging. Phenotypic screening, for example a screen based on human brown adipocyte function, may however facilitate the discovery of such a compound.

Finally, if an FGF21 analog with appropriate half-life and potency could be developed, it would enable PoC testing in humans in order to understand if the potential beneficial metabolic effects of this hormone can be realized.
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